Life Science Investing Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
Life Science Investing Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
Life Science Investing Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
life science investing Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
life science investing Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
life science investing Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635
